Company: DVAX
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001029142-25-000071
Chunk: 217

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 1
Chunk 217
---
 (Note 7)(3,938)- Payments for debt extinguishment (Note 7)(80,938)- Proceeds from unwind of capped call options (Note 7)46,554 - Payments for repurchase of common stock (Note 11)(29,465)- Proceeds from exercise of stock options6,503 1,635 Proceeds from Employee Stock Purchase Plan835 904 Payments for taxes related to net share settlement of restricted and performance stock units(11,141)(6,742)Net cash used in financing activities(31,882)(4,203)Effect of exchange rate changes on cash and cash equivalents, and restricted cash458 (201)Net decrease in cash and cash equivalents, and restricted cash(44,153)(18,252)Cash and cash equivalents, and restricted cash at beginning of period96,154 150,556 Cash and cash equivalents, and restricted cash at end of period$52,001 $132,304 Supplemental disclosure of cash flow information    Cash paid during the period for income taxes$413 $949 Cash paid during the period for interest$1,518 $- Non-cash investing and financing activities:    Purchases of property and equipment, not yet paid$2,046 $355 See accompanying notes.

8

Table of Contents

Dynavax Technologies Corporation 

Notes to Condensed Consolidated Financial Statements 

(Unaudited) 

1. Organization

Dynavax Technologies Corporation (“we,” “our,” “us,” “Dynavax” or the “Company”) is a commercial stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. Our first marketed product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted] is approved in the United States ("U.S."), the European Union ("EU") and the United Kingdom ("UK") for the prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older. In May 2022, we commenced commercial shipments of HEPLISAV-B in Germany. We are advancing a pipeline of differentiated product candidates that leverage our CpG 1018® adjuvant, the adjuvant used in HEPLISAV-B, to develop improved vaccines in indications with unmet medical needs. These programs currently include vaccine candidates under development for shingles and a plague vaccine candidate program in collaboration with